These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 16644082)
1. High-dose of multiple antipsychotics and cognitive function in schizophrenia: the effect of dose-reduction. Kawai N; Yamakawa Y; Baba A; Nemoto K; Tachikawa H; Hori T; Asada T; Iidaka T Prog Neuropsychopharmacol Biol Psychiatry; 2006 Aug; 30(6):1009-14. PubMed ID: 16644082 [TBL] [Abstract][Full Text] [Related]
2. Effects of antipsychotics on cognitive performance in drug-naive schizophrenic patients. Lee SM; Chou YH; Li MH; Wan FJ; Yen MH Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1101-7. PubMed ID: 17475386 [TBL] [Abstract][Full Text] [Related]
3. [Could we use a serum level of glycine as a prognostic factor of its efficacy in schizophrenic patients?]. Strzelecki D; Rabe-Jabłońska J Psychiatr Pol; 2010; 44(3):395-404. PubMed ID: 20672518 [TBL] [Abstract][Full Text] [Related]
4. Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia. Kim SW; Shin IS; Kim JM; Lee SH; Lee YH; Yang SJ; Yoon JS Hum Psychopharmacol; 2009 Oct; 24(7):565-73. PubMed ID: 19790174 [TBL] [Abstract][Full Text] [Related]
5. Relative contribution of antipsychotics, negative symptoms and executive functions to social functioning in stable schizophrenia. Rocca P; Montemagni C; Castagna F; Giugiario M; Scalese M; Bogetto F Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):373-9. PubMed ID: 19211031 [TBL] [Abstract][Full Text] [Related]
6. Neurocognitive effects of ziprasidone and related factors in patients with chronic schizophrenia undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial. Gibel A; Ritsner MS Clin Neuropharmacol; 2008; 31(4):204-20. PubMed ID: 18670244 [TBL] [Abstract][Full Text] [Related]
7. Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder. Elie D; Poirier M; Chianetta J; Durand M; Grégoire C; Grignon S J Psychopharmacol; 2010 Jul; 24(7):1037-44. PubMed ID: 19164494 [TBL] [Abstract][Full Text] [Related]
8. Effects of warm-supplementing kidney yang (WSKY) capsule added on risperidone on cognition in chronic schizophrenic patients: a randomized, double-blind, placebo-controlled, multi-center clinical trial. Chen ZH; Wang GH; Wang XP; Chen RY; Wang HL; Yang MH; Huo YX; Mei HB Hum Psychopharmacol; 2008 Aug; 23(6):465-70. PubMed ID: 18536066 [TBL] [Abstract][Full Text] [Related]
9. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. Mishara AL; Goldberg TE Biol Psychiatry; 2004 May; 55(10):1013-22. PubMed ID: 15121486 [TBL] [Abstract][Full Text] [Related]
10. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies. Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596 [TBL] [Abstract][Full Text] [Related]
11. Effects of tapering of long-term benzodiazepines on cognitive function in patients with schizophrenia receiving a second-generation antipsychotic. Kitajima R; Miyamoto S; Tenjin T; Ojima K; Ogino S; Miyake N; Fujiwara K; Funamoto Y; Arai J; Tsukahara S; Ito Y; Tadokoro M; Anai K; Kaneda Y; Yamaguchi N Prog Neuropsychopharmacol Biol Psychiatry; 2012 Mar; 36(2):300-6. PubMed ID: 22122880 [TBL] [Abstract][Full Text] [Related]
12. A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia. Lee SW; Lee JG; Lee BJ; Kim YH Int Clin Psychopharmacol; 2007 Mar; 22(2):63-8. PubMed ID: 17293705 [TBL] [Abstract][Full Text] [Related]
13. Course of recovery of cognitive impairment in patients with schizophrenia: a randomised double-blind study comparing sertindole and haloperidol. Gallhofer B; Jaanson P; Mittoux A; Tanghøj P; Lis S; Krieger S Pharmacopsychiatry; 2007 Nov; 40(6):275-86. PubMed ID: 18030652 [TBL] [Abstract][Full Text] [Related]
14. Doubtful association of antipsychotic polypharmacy and high dosage with cognition in chronic schizophrenia. Kontis D; Theochari E; Kleisas S; Kalogerakou S; Andreopoulou A; Psaras R; Makris Y; Karouzos C; Tsaltas E Prog Neuropsychopharmacol Biol Psychiatry; 2010 Oct; 34(7):1333-41. PubMed ID: 20691745 [TBL] [Abstract][Full Text] [Related]
15. Changes in neurocognitive function in patients with schizophrenia after starting or switching to amisulpride in comparison with the normal controls. Ahn YM; Lee KY; Kim CE; Kim JJ; Kang DY; Jun TY; Choi JS; Chung IW; Kim SH; Hwang SS; Kim YS J Clin Psychopharmacol; 2009 Apr; 29(2):117-23. PubMed ID: 19512972 [TBL] [Abstract][Full Text] [Related]
16. Addition of memantine to antipsychotic treatment in schizophrenia inpatients with residual symptoms: A preliminary study. Krivoy A; Weizman A; Laor L; Hellinger N; Zemishlany Z; Fischel T Eur Neuropsychopharmacol; 2008 Feb; 18(2):117-21. PubMed ID: 17728110 [TBL] [Abstract][Full Text] [Related]
17. Clinical correlates of antipsychotic polytherapy in patients with schizophrenia in Singapore. Sim K; Su A; Chan YH; Shinfuku N; Kua EH; Tan CH Psychiatry Clin Neurosci; 2004 Jun; 58(3):324-9. PubMed ID: 15149301 [TBL] [Abstract][Full Text] [Related]